Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ravi

Showing results (401-410 of 402) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 402 results.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Indian Heart Journal|April 13, 2017
Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in IndiaSantanu Guha, Rishi Sethi, Saumitra Ray, et al.
Pageof 41

Showing results (401-410 of 402) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 402 results.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Indian Heart Journal|April 13, 2017
Cardiological Society of India: Position statement for the management of ST elevation myocardial infarction in IndiaSantanu Guha, Rishi Sethi, Saumitra Ray, et al.
Pageof 41